Ronald Petersen (United States of America)
Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Cora Kanow Professor of Alzheimer’s Disease Research Director, Mayo Alzheimer’s Disease Research Center Mayo Clinic College of Medicine Rochester, MN Dr. Ronald C. Petersen received a Ph.D. from the University of Minnesota and graduated from Mayo Medical School in 1980. He completed an internship in Medicine at Stanford University Medical Center and returned to the Mayo Clinic to complete a residency in Neurology. That was followed by a fellowship in Behavioral Neurology at Harvard University Medical School/Beth Israel Hospital in Boston, Massachusetts. Dr. Petersen was named the Cora Kanow Professor of Alzheimer’s Disease Research and Mayo Clinic Distinguished Investigator in 2011. He is currently the Director of the Mayo Alzheimer’s Disease Research Center and the Mayo Clinic Study of Aging and has authored over 1000 peer-reviewed articles on memory disorders, aging, and Alzheimer’s disease. Dr. Petersen has received the 2004 MetLife Award for Medical Research in Alzheimer’s Disease and the 2005 Potamkin Prize for Research in Picks, Alzheimer’s and Related Disorders of the American Academy of Neurology. In 2012 he received the Khachaturian Award and the Henry Wisniewski Lifetime Achievement Award in 2013 from the Alzheimer’s Association. In 2011 he was appointed by the Secretary of Health and Human Services to serve as the Chair of the Advisory Committee on Research, Care and Services for the National Alzheimer’s Disease Plan.

Presenter of 1 Presentation

 Conference Calendar

PRE-RECORDED: CLINICAL AND BIOMARKER COMBINATIONS FOR EARLY ALZHEIMER’S DISEASE TRIALS

Session Name
1730 - DIAGNOSTIC ACCURACY, IMAGING AND FLUID BIOMARKERS IN AD, PD, LBD (ID 89)
Session Type
SYMPOSIUM
Date
Sat, 19.03.2022
Session Time
05:15 PM - 07:15 PM
Room
ONSITE PLENARY: 115-117
Lecture Time
06:30 PM - 06:45 PM
Presenter

Abstract

Abstract Body

The trend in Alzheimer’s disase (AD) trials is to identify the earliest features of impending cognitive decline with the goal of intervening early. Toward that end, a combination of clinical features along with biomarkers will be needed to develop and optimize recruitment plans. The prediction data from various studies in the field will be reviewed to determine which combinations of measures are most indicative of a clinical progression in randomized controlled trials. In addition, the data from the Mayo Clinic Study of Aging (MCSA) will be presented. The MCSA is a population-based study in Olmsted County, Minnesota, that enrolls persons ages 30 to 89 years who are normal or have mild cognitive impairment. We have acquired cognitive, imaging and fluid biomarkers on the participants and have longitudinal data to discuss. Consideration of medical comorbidities that may influence the interpretation of fluid biomarkers data will be discussed, and the application of these data to different stages of the clinical continuum will be evaluated. It is likely that different fluid biomarkers may be predictive at various stages in the AD process. For example, Aβ 42/40 may be useful in the preclinical phases of the disease while various P-tau measures may be more informative later in the progression of the disease. Considerations of applications of these data to underrepresented groups will be discussed, as well, since different models may be needed for various populations.
Hide